PURE Bioscience Reports Fourth Quarter and Year E... ( SAN DIEGO Oct. 15 /- PURE Bioscie...)

PURE Bioscience Reports Fourth Quarter and Year End Results

Date:10/15/2008

SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE), creators of the patented antimicrobial, silver dihydrogen citrate (SDC), today reported revenues for the fiscal year ended July 31, 2008 of $1,487,500, which increased more than 340% compared with $336,400 in the prior fiscal year. The Company reported a loss from operations before taxes of $(6,540,300), or $(0.24) per share, compared with a loss of $(4,654,900), or $(0.19) per share, in the prior year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO)

Included in the loss from operations before taxes for the fiscal year ended July 31, 2008 was $2,638,000 of non-cash expense, including stock-based compensation, amortization and depreciation, compared with $1,796,900 of such non-cash expense for the year ended July 31, 2007.

During the fourth quarter of its fiscal year, PURE announced new distribution agreements with Orchem Corporation and DuraBan International, two recognized organizations with established sales channels which will shortly begin to market SDC-based products. In addition, the Company announced that its distribution partner in Brazil had received approval to manufacture and sell SDC-based disinfectant. Finally, PURE entered into an agreement with FTA Therapeutics, LLC for the development and licensing of additional silver dihydrogen citrate (SDC)-based products for human use. FTA has already begun initial formulation and clinical projects for FDA-regulated dermatology, wound care and medical biofilm control products containing SDC.

Earlier in the year, the company signed an agreement with Rockline Industries, Inc., for North American distribution of PURE's ready-to-use disinfectant product and for the development and North American distribution of wipes products as well as new disinfectant, sanitizer and preservative products containing SDC. R
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. PURE Bioscience to Announce Fourth Quarter and Fiscal 2008 Results
2. Pressure BioSciences, Inc. Provides Corporate Update
3. Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
4. Dr. Charles Sanders to Become Lead Director of Epiphany Biosciences
5. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
6. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
7. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
8. Nomad Bioscience Announces Broad License Agreement
9. LI-COR Biosciences Offers $1.75 Million in Matching Funds for Undergraduate Genomics Education
10. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
11. Tethys Bioscience Announces Acquisition of Lipomics Technologies

Post Your Comments:

PURE Bioscience Reports Fourth Quarter and Year E...( SAN DIEGO Oct. 15 /- PURE Bioscie...)